

Notice

An Act respecting prescription drug insurance
(chapter A-29.01)

End of insurance coverage of medications

HAVING REGARD TO section 60.0.4 of the Act respecting prescription drug insurance
(chapter A-29.01);

HAVING REGARD TO the power of the Minister to suspend the insurance coverage of a medication, to end it or to not re-enter it, notably where a medication is subject to a listing agreement;

CONSIDERING that generic drugs competing with a generic drug of the manufacturer Neourne Pharma are the subject to a listing agreement pursuant to subparagraph 3 of paragraph 1 of section 60.0.4 of the Act respecting prescription drug insurance;

CONSIDERING that these competing generic drugs are produced by the following manufacturers:

Competing manufacturers	DIN	Brand name	Form	Strength
Jamp Pharma Corporation	80015847	Cal-Os D	Tablet	500 mg - 800 UI
Laboratoire Riva Inc.	80015972	Calcite 500 + D 800	Tablet	500 mg - 800 UI
Laboratoires Odan Ltd.	80024948	Nu-Cal D 800	Tablet	500 mg - 800 UI
Mantra Pharma Inc.	80019533	MCal D800	Tablet	500 mg - 800 UI
Jamp Pharma Corporation	80028413	Liqui-Jamp Plus	Capsule	500 mg - 800 UI
Mayaka International Inc.	80024378	LiquiCal-D	Capsule	500 mg - 800 UI

The Minister of Health and Social Services hereby gives notice of the end of the insurance coverage of the following generic drug of the manufacturer Neourne Pharma:

Manufacturer	DIN	Brand name	Form	Strength	Size
Neourne Pharma	80017422	U-Cal D800	Tablet	500 mg - 800 UI	100

This notice will come into force on 15 December 2017.

Québec, 29 November 2017

Original signed by

GAÉTAN BARRETTE
Minister of Health and Social Services